Future clinical directions will likely focus on standardized protocols, improved formulation quality, and clearer delineation between evidence-supported and investigational uses
doi: 10.3389/fphar.2025.1540255 82 GuDYiHJiangKFakharSHShiJHeYet al
Systolic (SBP) and diastolic blood pressure (DBP) were also consistently reduced by incretin-based drugs, ranging from 3.1 and 0.57 mmHg with liraglutide 3.0 mg to 9.2 and 5.1 mmHg with retatrutide, respectively
reduced soreness Week 4-6 Significant improvement in chronic injuries
Its non-hormonal mechanism of action, low risk of side effects, and broad range of healing applications make it a go-to for athletes, lifters, and individuals recovering from wear and tear
Q10: How does tirzepatide compare to semaglutide